Dr Moopen’s family raises stake in India’s Aster DM Healthcare
Dr Moopen’s family bought four per cent of shares from an un-named private equity investor for INR 4.6 billion, raising their stake in.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Dr Moopen’s family bought four per cent of shares from an un-named private equity investor for INR 4.6 billion, raising their stake in.
Novartis AG, the world's fourth-largest pharmaceutical company by revenue, announced its Kisqali drug reduced breast cancer recurrence when diagnosed at an early stage.
The WHO has issued a medical product alert on a contaminated cancer and autoimmune disease treatment drug made by Hyderabad, India-based Celon Laboratories,.
BioNTech, a Germany-based biotechnology company, is expected to spend between 2.4 million euros and 2.6 million euros on research this year compared with.
A nasal spray developed by Finnish researchers can prevent COVID-19 disease caused by all known variants and stop the transmission of the virus, according to.
A ransomware group has breached the information security network of India's Sun Pharmaceuticals unit, and there is a possibility that "file systems, business and personal.
The US FDA plans to permit the use of salt substitutes in daily food, such as bread, cheeses and ketchup, to reduce the.
Smokers may benefit from Sanofi's asthma drug after a phase III trial showed "significant improvements in lung function, quality of life" and uncontrolled.
The pill, revumenib, has shown benefit in treating both adults and children with certain type of acute leukemia.
BioNTech, a German immunotherapy company, announced a strategic pact with OncoC4, a private firm, to develop and commercialise a drug to treat solid tumours.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com